IQVIA’s Orchestrated Customer Engagement Selected by Novo Nordisk International Operations
November 27 2018 - 8:00AM
Business Wire
Leading diabetes company plans deployment of
IQVIA’s OCE technology solution to transform engagement with
healthcare professionals and to improve the value of every client
interaction
IQVIA™ (NYSE:IQV) today announced that Novo Nordisk, a global
healthcare company with nearly a century of innovation and
leadership in diabetes care, has selected IQVIA’s market-leading
Orchestrated Customer Engagement platform for deployment across
Novo Nordisk International Operations.
IQVIA Technologies’ OCE for next-generation customer engagement
seamlessly connects marketing, sales, medical science liaisons,
account management and other functions to enhance the customer
experience, strengthen relationships and drive performance. IQVIA
customers also benefit from more accurate decision-making through
predictive analytics, machine learning and optimized performance.
OCE is built on best-in-class platforms, including Salesforce.com,
MuleSoft, Amazon Web Services, Heroku and Box.
Novo Nordisk plans to switch its existing platforms to OCE in
2019 and beyond for this global rollout, excluding Canada and the
U.S., enabling them to streamline processes, further develop
customer relationships and better anticipate, and respond to market
changes.
About IQVIAIQVIA (NYSE:IQV) is a leading global provider
of advanced analytics, technology solutions and contract research
services to the life sciences industry. Formed through the merger
of IMS Health and Quintiles, IQVIA applies human data science —
leveraging the analytic rigor and clarity of data science to the
ever-expanding scope of human science — to enable companies to
reimagine and develop new approaches to clinical development and
commercialization, speed innovation and accelerate improvements in
healthcare outcomes. Powered by the IQVIA CORE™, IQVIA delivers
unique and actionable insights at the intersection of large-scale
analytics, transformative technology and extensive domain
expertise, as well as execution capabilities. With more than 55,000
employees, IQVIA conducts operations in more than 100
countries.
IQVIA is a global leader in protecting individual patient
privacy. The company uses a wide variety of privacy-enhancing
technologies and safeguards to protect individual privacy while
generating and analyzing the information that helps its customers
drive human health outcomes forward. IQVIA’s insights and execution
capabilities help biotech, medical device and pharmaceutical
companies, medical researchers, government agencies, payers, and
other healthcare stakeholders tap into a deeper understanding of
diseases, human behaviors, and scientific advances, in an effort to
advance their path toward cures. To learn more, visit
www.iqvia.com.
About Novo NordiskNovo Nordisk is a global healthcare
company with 95 years of innovation and leadership in diabetes
care. This heritage has given us experience and capabilities that
also enable us to help people defeat obesity, haemophilia, growth
disorders and other serious chronic diseases. Headquartered in
Denmark, Novo Nordisk employs approximately 43,200 people in 79
countries and markets its products in more than 170 countries. For
more information, visit novonordisk.com, Facebook, Twitter,
LinkedIn, YouTube.
IQVIAFIN
Click here to subscribe to Mobile Alerts for IQVIA.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20181127005258/en/
Tor Constantino, IQVIA Media Relations
(tor.constantino@iqvia.com)+1.484.567.6732
Andrew Markwick, IQVIA Investor Relations
(andrew.markwick@iqvia.com)+1.973.257.7144
IQVIA (NYSE:IQV)
Historical Stock Chart
From Jun 2024 to Jul 2024
IQVIA (NYSE:IQV)
Historical Stock Chart
From Jul 2023 to Jul 2024